Andrew Tobin

Dr Andrew Tobin is Professor of Molecular Pharmacology at the University of Glasgow, where, he established Centre for Translational Pharmacology which aimed at drawing together his research interests in G-protein Coupled Receptors (GPCRs) and protein kinases into a Centre focused on defining the novel paradigms in pharmacology that will allow for the rational design of next generation drugs. The Tobin Group has its GPCR research focuses on the mechanism and function of post-translational modification of the GPCR receptors, in vitro and in vivo, with the aid of novel genetic mouse strains, mouse disease models and novel pharmacological entities. They aim to disclose more insights, as well as therapeutic potential of GPCRs. In parallel, Dr Tobin also leads research on phospho-signalling cascades in malaria and methods to target these in the development of next generation anti-malarials.

Lab Information

Institute of Molecular, Cell and Systems Biology University of Glasgow

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Antimalarial 0 GPCR Signalling 0 Protein Phosphorylation 0 GPCR-based Drug for Neurodegenerative Diseases 0 Proteomics 0 Genetic Engineering 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Bradley SJ, Molloy C, Valuskova P, et al. Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nat Chem Biol. 2020;16(3):240-249. doi:10.1038/s41589-019-0453-9

  2. Thompson KJ, Tobin AB. Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?. Cell Signal. 2020;70:109545. doi:10.1016/j.cellsig.2020.109545

  3. Alam MM, Sanchez-Azqueta A, Janha O, et al. Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science. 2019;365(6456):eaau1682. doi:10.1126/science.aau1682

  4. Bradley SJ, Bourgognon JM Sanger HE Verity N, Mogg AJ, White DJ, Butcher AJ Moreno JA, Molloy C, Macedo-Hatch T, Edwards JM, Wess J, Pawlak R, Read DJ, Sexton PM, Broad LM, Steinert RJ, Mallucci GR, Christopoulos A, Felder CC, Tobin AB. M1-muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss. J. Clin. Invest. (2017) 127(2):487-499.

  5. Mitcheson DF, Bottrill AR, Bayliss R, Carr K, Coxon CR¶, Cano C, Golding BT¶, Griffin RJ, Fry AM, Doerig C, Tobin AB. A new tool for the chemical genetic investigation of Pfnek2 in Plasmodium falciparum. Malaria Journal. (2016) 15(1):535.

  6. Prihandoko R, Alvarez-Curto E, Hudson BD, Butcher AJ, Ulven T, Miller AM, Tobin AB, Milligan G: Distinct phosphorylation clusters determines the signalling outcome of the free fatty acid receptor FFA4/GPR120. Mol Pharmacol (2016) 89(5):505-20.


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud